Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,400.96
(
-0.16%
)
US TECH 100
28,196.00
(
-1.18%
)
Dow Jones
49,760.56
(
0.11%
)
Brent Oil
104.52
(
-1.17%
)
Bitcoin
81,073.48
(
0.72%
)
News Focus
News Focus
Post# of 6105
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122973
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 5928

Wednesday, 04/29/2026 10:20:50 AM

Wednesday, April 29, 2026 10:20:50 AM

Post# of 6105
ABBV’s 1Q26 Mavyret sales=$351M, +9% YoY in_constant_currency:

https://www.prnewswire.com/news-releases/abbvie-reports-first-quarter-2026-financial-results-302757172.html

The geographic breakdown: US $183M, +28% YoY; ex-US $168M, -9% YoY in constant currency.

Clearly, the Mavyret’s approved indication for acute HCV continues to drive growth in the US market.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent ENTA News
More ENTA News